Short-term effectiveness prognostic factors after dexamethasone intravitreal implant in macular edema due to retinal vein occlusion.

Abstract

INTRODUCTION\nThe aim of this study was to describe functional and anatomical changes (best-corrected visual acuity [BCVA], central macular thickness [CMT], and central macular volume [CMV]) in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) treated with intravitreal dexamethasone implant (IDI) and identify its clinical predictors in a real-world setting.\n\n\nMETHODS\nData from 111 patients who underwent IDI to treat RVO-associated ME were retrospectively reviewed. Demographic, preoperative, and postoperative variables were assessed using a logistic regression analysis to determine predictors of visual and anatomical improvement.\n\n\nRESULTS\nMean BCVA, CMT, and CMV improved from baseline after IDI (p\u2009<\u20090.001). The strongest predictors of different treatment outcomes were: a baseline BCVA ⩽60 ETDRS letters (OR\u2009=\u200950.600; p\u2009<\u20090.001) and first IDI injection (OR\u2009=\u20092.988; p\u2009<\u20090.001) for BCVA gain ⩾15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; a baseline BCVA ⩽60 ETDRS letters (OR\u2009=\u20097.893; p\u2009=\u20090.002) and non-chronic ME (OR\u2009=\u20093.875; p\u2009=\u20090.019) for BCVA ⩾80 ETDRS letters achievement; a baseline CMT ⩾400\u2009µm (OR\u2009=\u200949.083; p\u2009<\u20090.001) and a baseline CMV ⩾12\u2009mm3 (OR\u2009=\u20094.235; p\u2009<\u20090.001) for CMT reduction ⩾50%; and a baseline CMT ⩾400\u2009µm (OR\u2009=\u200911.471; p\u2009<\u20090.001) and a baseline CMV ⩾12\u2009mm3 (OR\u2009=\u200910.284; p\u2009<\u20090.001) for CMV reduction ⩾15%.\n\n\nCONCLUSION\nThis study confirmed the effectiveness of IDI to treat ME secondary to RVO and identified new predictive factors for two visual (⩾15 ETDRS letters gain and BCVA ⩾80 ETDRS letters) and two anatomical outcomes (>50% CMT and >15% CMV reduction).